Cell Cycle

Cell cycle is the entire process of cell division from the completion of one division to the end of the next division and is divided into two phases: interphase and division. Life is a continuous process passed from generation to generation and is therefore a process of constant renewal and starting from scratch. Thus, it is a process of constant renewal and starting from scratch. The life of a cell begins with the division of its parent cell and ends with the formation of its daughter cells, or the death of the cell itself. Usually, the formation of daughter cells is considered to mark the end of cell division. The cell cycle is the process from the formation of daughter cells at one cell division to the formation of daughter cells at the next cell division. During this process, the genetic material of the cell is copied and distributed equally to the two daughter cells.

Cat. No.	Product name
BP13469	ROCK2-IN-2
BP13469	ROCK2-IN-2 is a selective inhibitor of ROCK2 (IC50 of <1 μM).
BP13470	Roniciclib
BP13470	Roniciclib is a potent pan-CDK inhibitor and a novel oral cytotoxic agent. Roniciclib inhibits the activity of cell-cycle CDKs CDK1, CDK2, CDK3, CDK4, and of transcriptional CDKs CDK7 and CDK9 with IC(50) values in the range between 5 and 25 nmol/L.
BP13471	Seliciclib
BP13471	Roscovitine is a potent inhibitor of Cdk2/cyclin E (IC50: 0.1 μM). It also inhibits Cdk7/cyclin H, Cdk5/p35, and Cdc2/cyclin B (IC50s: 0.49/0.16/0.65 μM).
BP13472	RX-3117
BP13472	RX-3117 is a novel a cytidine analog. RX-3117 displays anticancer activity in several cancer cell lines, including gemcitabine-resistant variants.
BP13473	sAJM589
BP13473	sAJM589 is a Myc inhibitor(IC50: 1.8 μM).
BP13474	Sanggenol L
BP13474	Sanggenol L shows higher cytotoxicity against human oral tumor cell lines (HSC-2 and HSG) than against normal human gingival fibroblasts (HGF), it induces apoptosis via caspase activation and inhibition of NF-κB/IκBα± phosphorylation as a potent chemotherapeutic agent for ovarian cancers.
BP13475	Sangivamycin
BP13475	Sangivamycin is an effective inhibitor of protein kinase C (PKC, Ki = 10 μM). Sangivamycin exhibits antiproliferative activity against a variety of human cancers.
BP13476	Sapacitabine
BP13476	Sapacitabine is a nucleoside analog prodrug with antitumor activity.
BP13477	SAR-020106
BP13477	SAR-020106 is a potent, ATP-competitive, and selective CHK1 inhibitor with an IC50 of 13.3 nmol/L on the isolated human enzyme.
BP13478	SAR407899 hydrochloride
BP13478	SAR407899 hydrochloride is a selective, potent and ATP-competitive ROCK inhibitor, with an IC50 of 135 nM for ROCK-2, and Kis of 36 nM and 41 nM for human and rat ROCK-2, respectively.
BP13479	SAR407899
BP13479	SAR407899 is Rho kinase inhibitor potently inhibits endothelin-1-induced constriction of renal resistance arteries.
BP13480	SB-218078
BP13480	SB-218078 is less potently inhibits Cdc2 (IC50: 250 nM) and PKC (IC50: 1000 nM). SB-218078 is a potent, ATP-competitive, and cell-permeable checkpoint kinase 1 inhibitor that inhibits Chk1 phosphorylation of cdc25C (IC50: 15 nM).
BP13481	SB-743921 hydrochloride
BP13481	SB-743921 is an effective inhibitor of kinesin spindle protein, KSP, (Ki =0.1 nM).
BP13482	SB-772077B dihydrochloride
BP13482	SB-772077B dihydrochloride is an aminofurazan-based Rho kinase inhibitor (IC50s: 5.6 nM and 6 nM toward ROCK1 and ROCK2, respectively).
BP13483	SBC-110736
BP13483	SBC-110736 is a proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitor
BP13484	SBC-115076
BP13484	SBC-115076 is a potent extracellular proprotein convertase subtilisin kexin type 9 (PCSK9) antagonist.
BP13485	SBC-115337
BP13485	SBC-115337 is a PCSK9 inhibitor.
BP13486	SC-514
BP13486	SC-514 is a selective, orally active, ATP-competitive IKK-2 inhibitor (IC50=11.2±4.7 μM), obstructs NF-κB-dependent gene expression.
BP13487	SCH-1473759 hydrochloride
BP13487	SCH-1473759 hydrochloride is an inhibitor of aurora(aurora A and B with IC50s of 4 and 13 nM, respectively).
BP13488	SCH-1473759
BP13488	SCH-1473759 is an inhibitor of the aurora (IC50s: 4 and 13 nM for Aurora A and B, respectively).